Exane Derivatives Bristol Myers Squibb CO Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Exane Derivatives holds 17,094 shares of BMY stock, worth $832,477. This represents 0.84% of its overall portfolio holdings.
Number of Shares
17,094
Previous 10,833
57.8%
Holding current value
$832,477
Previous $791,000
66.37%
% of portfolio
0.84%
Previous 0.24%
Shares
20 transactions
Others Institutions Holding BMY
# of Institutions
2,399Shares Held
1.5BCall Options Held
29.7MPut Options Held
32.2M-
Vanguard Group Inc Valley Forge, PA187MShares$9.09 Billion0.15% of portfolio
-
Black Rock Inc. New York, NY159MShares$7.73 Billion0.15% of portfolio
-
State Street Corp Boston, MA91.4MShares$4.45 Billion0.17% of portfolio
-
Jpmorgan Chase & CO New York, NY74.6MShares$3.63 Billion0.27% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA59.1MShares$2.88 Billion0.47% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $104B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...